CD274 and neoplasm: Also, recent preliminary results presented in the congress of European Society for Medical Oncology suggests that tumor mutation burden, neoantigen load, and PD‐L1 expression are similar in MSI primary tumors and in metastases explaining the benefits of immune therapy seen across different metastatic sites [33].